CAF-Derived Lactate Orchestrates Oxaliplatin Resistance in Colorectal Cancer via ANTXR1 Lactylation

Study Background and Research Question

Colorectal cancer (CRC) is a leading cause of cancer mortality, accounting for approximately 9.3% of all cancer deaths globally (paper). Oxaliplatin-based chemotherapy remains a cornerstone for treating both metastatic and non-metastatic CRC. However, clinical resistance to oxaliplatin undermines its effectiveness, with up to 40% of advanced CRC patients exhibiting primary or secondary resistance and roughly 20–30% of non-metastatic cases relapsing post-treatment (paper). The tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), has emerged as a key contributor to both cancer progression and drug resistance. The present study addresses a central question: How do CAFs influence oxaliplatin resistance in CRC, and what molecular mediators are involved?

Key Innovation from the Reference Study

The principal innovation of this research is the identification of a specific metabolic and epigenetic interaction: lactate secreted by CAFs induces resistance to oxaliplatin in CRC cells through a mechanism involving ANTXR1 (Anthrax Toxin Receptor 1) lactylation. This study is the first to demonstrate that CAF-derived lactate not only enhances transcription of ANTXR1 via histone lactylation but also directly promotes its post-translational lactylation at lysine 453 (K453). This dual regulation stabilizes ANTXR1 protein and triggers downstream signaling that enhances cancer stemness—an established driver of chemoresistance (paper).

Methods and Experimental Design Insights

The study employs a multifaceted approach combining molecular biology, cell culture, and in vivo models:

• CAF Isolation and Characterization: CAFs were derived from human CRC tissues and validated for glycolytic activity and lactate secretion.
• Co-Culture Systems: CRC cells were co-cultured with CAFs to recapitulate the tumor microenvironment, enabling the study of paracrine lactate effects.
• Drug Sensitivity Assays: Oxaliplatin sensitivity was measured in CRC cells exposed to CAF-conditioned media or exogenous lactate.
• Gene and Protein Expression: Levels of ANTXR1, stemness markers (LGR5, CD133, CD44), and lactylation-modified ANTXR1 (K453la) were assessed by qPCR, immunoblotting, and immunostaining.
• Functional Pathway Analysis: Modulation of the RhoC/ROCK1/SMAD5 axis was evaluated in response to altered ANTXR1 lactylation.
• Genetic and Pharmacological Interventions: Inhibition of lactate transport and ANTXR1 expression was achieved via shRNA and small molecule inhibitors.
• In Vivo Validation: The role of CAF-derived lactate and ANTXR1 lactylation was confirmed in mouse xenograft models using both cell-derived and patient-derived CRC tumors (paper).

Protocol Parameters

• CAF-CRC cell co-culture duration | 48–72 hours | Tumor microenvironment modeling | Optimal for paracrine metabolite exchange and gene expression changes | paper
• Lactate supplementation | 10 mM | Chemoresistance induction assay | Mimics physiologic concentrations found in glycolytic tumors | paper
• Oxaliplatin exposure | 10–20 μM | Drug sensitivity assay | Reflects clinically relevant cytotoxicity ranges for in vitro CRC studies | paper
• Gene expression quantification | RT-qPCR (standardized protocols) | Stemness and resistance marker quantification | Ensures reproducibility in transcriptomic profiling | workflow_recommendation
• DNA removal for RNA extraction | DNase I (RNase-free), 1 U/μg RNA | RNA integrity and downstream transcriptomic analysis | Prevents DNA contamination in RT-PCR and expression studies | workflow_recommendation

Core Findings and Why They Matter

The study demonstrates that CAFs with an activated glycolytic phenotype secrete elevated levels of lactate, which in turn:

1. Promotes histone lactylation at the ANTXR1 gene locus in CRC cells, increasing its transcription.
2. Induces lactylation of ANTXR1 protein at lysine 453, enhancing protein stability and activity.
3. Triggers the RhoC/ROCK1/SMAD5 signaling pathway, which is implicated in maintaining cancer stem cell (CSC) properties and drug resistance.
4. Correlates high ANTXR1 and K453la levels with oxaliplatin resistance and poor prognosis in CRC patients (paper).
5. Shows that disrupting the CAF–CRC lactate shuttle, either genetically or pharmacologically, sensitizes tumors to oxaliplatin in vitro and in xenograft models.

The elucidation of this axis not only clarifies a molecular mechanism behind chemoresistance but also identifies potential therapeutic targets—namely, lactate metabolism and ANTXR1 lactylation.

Comparison with Existing Internal Articles

Recent internal articles have underscored the necessity of robust nucleic acid sample preparation tools in high-fidelity oncology research. For example, the article "Mechanistic Mastery and Strategic Deployment: DNase I (RNase-free) in Translational Oncology" discusses how accurate DNA removal is essential for studying cell-fibroblast interactions and chemoresistance using advanced 3D co-culture models. These workflows rely on ribonuclease-free DNase I to ensure that transcriptomic analyses are free from genomic DNA contamination—a critical consideration highlighted in the present study's RNA-based assays.

Similarly, "DNase I (RNase-free): Advanced Endonuclease for DNA Digestion" details the technical merits of DNase I (RNase-free) for DNA removal in RNA extraction and in vitro transcription sample preparation, reinforcing the importance of clean nucleic acid preps for downstream mechanistic studies like those employed in this CRC research. The present study's reliance on qPCR, immunoblotting, and functional assays aligns with these best practices and illustrates the translational value of high-quality sample processing reagents.

Limitations and Transferability

While the study robustly characterizes the CAF–CRC–lactate–ANTXR1 axis, several limitations merit consideration:

• Model Generalizability: Although both cell line-based and patient-derived xenograft models were used, further validation in diverse patient cohorts and primary CAF populations is needed to confirm universality.
• Mechanistic Complexity: The study focuses primarily on lactate and ANTXR1 but does not fully explore other stromal-derived metabolites or post-translational modifications that may contribute to resistance.
• Therapeutic Targeting: While lactate transport and ANTXR1 inhibition improved oxaliplatin sensitivity in preclinical models, the clinical safety and efficacy of such interventions remain to be established.

Nevertheless, these findings provide a mechanistic basis for further investigation and development of stromal-targeted therapies to overcome chemoresistance in CRC (paper).

Research Support Resources

To ensure RNA-based assays such as RT-qPCR and transcriptomic profiling are free from DNA contamination—a prerequisite for accurate stemness and resistance marker quantification—researchers can employ DNase I (RNase-free) (SKU K1088) during RNA extraction and sample preparation. As highlighted in both the current study and internal resources, rigorous DNA removal supports reproducibility and reliability in gene expression analyses central to chemoresistance investigations (internal article). For protocols involving chromatin digestion or in vitro transcription, this ribonuclease-free DNase I is also applicable, helping to maintain the integrity of RNA and protein analyses essential for mechanistic cancer research workflows.